Syntara (ASX:SNT) Treasury Stock : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Syntara's treasury stock for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Syntara Treasury Stock Historical Data

The historical data trend for Syntara's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Treasury Stock Chart

Syntara Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Treasury Stock

Get a 7-Day Free Trial

Syntara Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Syntara Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Syntara (ASX:SNT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.